Sun Pharmaceutical standalone Q2 net down to Rs 888.6 crore
The company's Board also approved the Scheme of Arrangement for amalgamation of five subsidiaries into Sun Pharmaceutical and reclassification of general reserves to retained earnings, subject to necessary approvals.
Pharma major Sun Pharmaceutical Industries Ltd on Wednesday said it closed Q2FY24 with lower operational revenue and net profit as compared to Q2FY23.
In a regulatory filing, the company said for the quarter ended 30.9.2023 it had booked a standalone operational revenue of Rs. 5,096.2 crore (Q2FY23 Rs.5,282.2 crore) and a net profit of Rs.888.6 crore (Rs.1,213 crore).
The company's Board also approved the Scheme of Arrangement for amalgamation of five subsidiaries into Sun Pharmaceutical and reclassification of general reserves to retained earnings, subject to necessary approvals.
The amalgamation of the subsidiaries has been decided to simplify the group structure.
The wholly-owned subsidiaries are: Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited and Skisen Labs Private Limited.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Power of Compounding: How many years will it take to reach Rs 3 crore corpus if your monthly SIP is Rs 4,000, Rs 5,000, or Rs 6,000
Power of Compounding: Salary Rs 25,000 per month; is it possible to create over Rs 2.60 crore corpus; understand it through calculations
Reduce Home Loan EMI vs Reduce Tenure: Rs 75 lakh, 25-year loan; which option can save Rs 25 lakh and 64 months and how? Know here
Top 7 Large and Mid Cap Mutual Funds with Best SIP Returns in 5 Years: No. 1 fund has turned Rs 15,000 monthly SIP investment into Rs 20,54,384; know about others
New Year Pick by Anil Singhvi: This smallcap stock can offer up to 75% return in long term - Check targets
PSU Oil Stocks: Here's what brokerage suggests on these 2 largecap, 1 midcap scrips - Buy, Sell or Hold?
08:34 PM IST